Latest News and Press Releases

GAITHERSBURG, Md. and BASEL, Switzerland, March 12, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS), a leading public health company that delivers protective and life-saving...

GAITHERSBURG, Md., March 10, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has entered into an agreement to sell its Baltimore-Bayview drug substance...

Fourth Quarter 2024 Total Revenues of $194.7 million; Full Year 2024 Total Revenues of $1.04 billionFourth Quarter 2024 Net Loss of $31.3 million, decrease in Net Loss of 37% versus prior yearFourth...

GAITHERSBURG, Md., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Monday, March 3, 2025, at 5:00 pm eastern time to discuss the financial...

Despite the recently reported national decline in opioid overdose deaths, many U.S. communities, including New Orleans, continue to see an increase in accidental drug-related deaths year over year ...

Africa CDC’s support for the MOSA has enabled the enrollment of the first patients at Mbandaka Hospital in Equateur Province, Democratic Republic of Congo.

Alongside over-the-counter NARCAN® Nasal Spray 4 mg, prescription KLOXXADO® (naloxone HCl) Nasal Spray 8 mg will expand Emergent’s ability to distribute multiple life-saving opioid overdose emergency...

This option is part of Emergent’s existing 10-year contract with BARDA for advanced development and procurement of Ebanga™, with a maximum value of $704 millionProgram progress and performance...

GAITHERSBURG, Md., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS), a leading public health company that delivers protective and life-saving solutions to communities across the...

Emergent BioSolutions today announced the exercise of contract option and modification valued at approximately $20 million to supply BioThrax®